#Germany #Frankfurt #Traditional Chinese Medicine #CPHI Frankfurt #Taiwan TCM

Taiwan's Traditional Chinese Medicine Shines at CPHI Frankfurt 2025

Taiwan's participation in CPHI Frankfurt 2025 marked a significant milestone in its journey to promote Traditional Chinese Medicine (TCM) on a global scale. The pavilion, orchestrated by the Department of Chinese Medicine and Pharmacy (DCMP) under the Ministry of Health and Welfare (MOHW), drew considerable attention from international health professionals, reinforcing Taiwan's commitment to advancing evidence-based TCM.

From October 28 to 30, 2025, the Taiwan TCM Pavilion showcased a diverse range of Taiwanese TCM companies, fostering dynamic exchanges with visitors, including pharmaceutical experts and research institutions from around the world. The engagement emphasized collaboration in product distribution and Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM), creating new opportunities for global market expansion.

The pavilion attracted 121 specialized visitors over the three days of the exhibition and facilitated four business development sessions with five international companies, along with two business and investment organizations. These interactions not only highlighted Taiwan's innovative capabilities but also its potential for cross-border market engagements.

One of the pavilion's notable achievements was being selected for a live segment on the CPHI Newsbeat Stage, a rare opportunity that positioned Taiwan's advancements in TCM front and center on a major global media platform. During this session, Taiwanese representatives presented insights into the development of evidence-based TCM, followed by an interview with Raman Sehgal, host of the "Molecule to Market" podcast, attended by around ten media representatives. This raised the international visibility of Taiwan, further emphasizing its role in the global healthcare dialogue.

At the heart of Taiwan's TCM advancements are NRICM101 and NRICM102, two nationally recognized TCM formulations developed by the National Research Institute of Chinese Medicine (NRICM) and approved by the MOHW. Studies involving these formulations have been vetted by experts and shown to possess antiviral and anti-inflammatory properties, significantly reducing the likelihood of intensive care unit admissions and mortality rates among COVID-19 patients. Additionally, these formulations have protective effects against lung injuries and post-infection cognitive impairments, commonly known as 'Brain Fog.'

Taiwanese companies like Chuang Song Zong, Li Kang Biotech, Timing Pharmaceutical, Taiwan Three Mast, and Grape King Bio participated in this celebration of TCM, presenting Taiwan's robust ecosystem that encompasses clinical research, product innovation, and GMP-certified manufacturing capabilities along with global OEM/ODM services.

During the event, Mr. Mei-Shun Lo, Director General of the Taipei Representative Office in the Federal Republic of Germany, and Bertram Roth, Vice President of FrankfurtRheinMain GmbH, expressed their support for Taiwan's initiatives in evidence-based TCM and advocated for future collaborations with European partners. They recognized the promising potential of Taiwan's TCM industry in Germany and beyond.

Dr. Yi-Chang Su, Director of DCMP and NRICM, expressed optimism about Taiwan's success at CPHI Frankfurt, stating, "Our efforts to incorporate proven traditional medicine into the global health dialogue are underscored by our achievements here. We look forward to building on this momentum to expand cross-border collaboration and innovation in the field of TCM."

The transformation of Taiwan's TCM from pandemic innovation to collaborative global engagement reflects its strategic vision and unwavering commitment to improving global health outcomes through traditional practices. As a crucial player in the TCM landscape, Taiwan continues to leverage its unique heritage and cutting-edge research, promising abundant opportunities for future international partnerships.